Find Vadadustat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1000025-07-9, Akb-6548, Pg-1016548, Vadadustat [usan], N-(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, B506
Molecular Formula
C14H11ClN2O4
Molecular Weight
306.70  g/mol
InChI Key
JGRXMPYUTJLTKT-UHFFFAOYSA-N
FDA UNII
I60W9520VV

Vadadustat
Vadadustat is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, vadadustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.
1 2D Structure

Vadadustat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
2.1.2 InChI
InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
2.1.3 InChI Key
JGRXMPYUTJLTKT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
I60W9520VV
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Akb-6548

2.3.2 Depositor-Supplied Synonyms

1. 1000025-07-9

2. Akb-6548

3. Pg-1016548

4. Vadadustat [usan]

5. N-(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine

6. B506

7. Pg1016548

8. B-506

9. Akb6548

10. (5-(3-chlorophenyl)-3-hydroxypicolinoyl)glycine

11. I60w9520vv

12. 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic Acid

13. Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-

14. Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-

15. Vafseo

16. Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-;glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-

17. Unii-i60w9520vv

18. Us8722895, 11: {[5-(3-chlorophenyl)-3-hydroxypyridine-2- Carbonyl]amino}-acetic Acid

19. A1z

20. Vafseo (tn)

21. Vadadustat [inn]

22. Vadadustat [jan]

23. Us8722895, 10: {[5-(3-chlorophenyl)-3-hydroxypyridine-2- Carbonyl]amino}-acetic Acid Trifluoroacetic Acid Salt

24. Vadadustat [who-dd]

25. Vadadustat (jan/usan/inn)

26. Schembl1920738

27. Chembl3646221

28. Gtpl11831

29. Bdbm107704

30. Dtxsid501179936

31. Amy27885

32. Bcp19497

33. Ex-a2573

34. 2-{[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]formamido}acetic Acid

35. Gsk128863

36. S6490

37. Zinc117532869

38. Cs-6373

39. Db12255

40. Sb19204

41. Us8598210, Table Xv, 10

42. Us8598210, Table Xv, 11

43. Ac-30928

44. As-71695

45. Db-102455

46. Hy-101277

47. Vadadustat; Pg-1016548; Akb-6548

48. J3.560.572j

49. C71001

50. D11078

51. Us8598210, 119

52. Q27280485

53. 2-(5-(3-chlorophenyl)-3-hydroxypicolinamido)acetic Acid

54. Akb-6548; B-506; Pg-1016548

55. {[5-(3-chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic Acid

56. {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic Acid

2.4 Create Date
2008-01-07
3 Chemical and Physical Properties
Molecular Weight 306.70 g/mol
Molecular Formula C14H11ClN2O4
XLogP32.5
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass306.0407345 g/mol
Monoisotopic Mass306.0407345 g/mol
Topological Polar Surface Area99.5 Ų
Heavy Atom Count21
Formal Charge0
Complexity393
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of anaemia due to chronic disorders


5 Pharmacology and Biochemistry
5.1 ATC Code

B - Blood and blood forming organs

B03 - Antianemic preparations

B03X - Other antianemic preparations

B03XA - Other antianemic preparations

B03XA08 - Vadadustat


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Vadadustat

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content

Vadadustat

About the Company : Ami Lifesciences, established in 2006, is one of the fastest growing API manufacturing companies in India. Specializing in cardiovascular, anti-diabetic, CNS, and respiratory thera...

Ami Lifesciences, established in 2006, is one of the fastest growing API manufacturing companies in India. Specializing in cardiovascular, anti-diabetic, CNS, and respiratory therapeutic areas, Ami offers a wide range of APIs, intermediates, key starting materials, as well as contract bulk manufacturing services. Ami's manufacturing units in Gujarat and Karnataka feature dedicated clean rooms for APIs and adhere to international standards like EU-GMP, WHO-GMP, PMDA, and COFEPRIS. Ami serves as a reliable partner for contract development and manufacturing, offering generic APIs to global pharma companies across more than 60 countries.
AMI Lifesciences

03

HRV Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Vadadustat

About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Pharma effectively promote projects and products. HRV Pharma represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Pharma has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.

Flag India
Digital Content Digital Content

Vadadustat

About the Company : Maithri Drugs is one of India's fastest growing pharmaceutical companies, strategically focused on Active Pharmaceutical Ingredients (APIs). Backed by a strong R&D foundation, we h...

Maithri Drugs is one of India's fastest growing pharmaceutical companies, strategically focused on Active Pharmaceutical Ingredients (APIs). Backed by a strong R&D foundation, we hold over 150 Drug Master Files (DMFs) globally, including 54 US DMFs and 16 Certificates of Suitability (CEPs). Our state-of-the-art manufacturing facility in Hyderabad is approved by the US FDA and certified by DGCI, WHO GMP, and ISO 9001:2015. With a portfolio of over 65 APIs across therapeutic areas such as CNS, cardiovascular, anti-infectives, and anti-diabetics, we export to more than 35 countries, driven by quality, innovation, and long-term client trust.
Company Banner

05

Pharmaconex
Not Confirmed
arrow
arrow
Pharmaconex
Not Confirmed

Vadadustat

About the Company : Shanvr Life Sciences Pvt Ltd is a pharmaceutical product development company with a strong emphasis on research. Our approach centers around the creation of specialized generic, on...

Shanvr Life Sciences Pvt Ltd is a pharmaceutical product development company with a strong emphasis on research. Our approach centers around the creation of specialized generic, oncology, and specialty pharmaceuticals, utilizing various business models tailored to meet client needs. We collaborate with prominent national and international drug developers and manufacturers, providing them with cutting-edge development solutions and capabilities to ensure the production of safe drugs. As an R&D-focused enterprise,it is dedicated to the development of new generic pharmaceuticals and investigational medicinal products.
blank

06

Viatris

U.S.A
Pharmaconex
Not Confirmed
arrow

Viatris

U.S.A
arrow
Pharmaconex
Not Confirmed

Vadadustat

About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...

In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020.
blank

07

Pharmaconex
Not Confirmed
arrow
arrow
Pharmaconex
Not Confirmed

Vadadustat

About the Company : Zydus is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states...

Zydus is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil. Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709836200,"product":"PHARMACEUTICAL RAW MATERIAL AS PERPO NO. PRB-1126\/122023 - VADADUSTAT","address":"2 FLR.PRESTIGE PLAZA","city":"AKOTA BARODA","supplier":"AMI LIFESCIENCES PVT LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"AL ARAFAH ISLAMIBANK PLC","customerCountry":"BANGLADESH","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"10000","totalValueFC":"19651.8","currency":"USD","unitRateINR":815900,"date":"08-Mar-2024","totalValueINR":"1631800","totalValueInUsd":"19651.8","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8152287","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2 FLR.PRESTIGE PLAZA, AKOTA BARODA","customerAddress":""}]
08-Mar-2024
08-Mar-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

01

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 30, 2025

blank

Details:

The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Leerink Partners

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering March 19, 2025

blank

02

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Lead Product(s) : Vadadustat,Inapplicable

Therapeutic Area : Nephrology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Leerink Partners

Deal Size : Undisclosed

Deal Type : Public Offering

Details : The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 19, 2025

blank

Details:

The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Leerink Partners

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering March 19, 2025

blank

03

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Lead Product(s) : Vadadustat,Inapplicable

Therapeutic Area : Nephrology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Leerink Partners

Deal Size : $50.0 million

Deal Type : Public Offering

Details : The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 19, 2025

blank

Details:

Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: MEDICE Health Family

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 14, 2025

blank

04

Erkim

Turkey
arrow
Pharmaconex
Not Confirmed

Erkim

Turkey
arrow
Pharmaconex
Not Confirmed

Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

January 14, 2025

blank

Details:

Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 03, 2024

blank

05

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 03, 2024

blank

Details:

Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for anemia due to chronic kidney disease in adult patients on dialysis.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 07, 2024

blank

06

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for anemia due to chronic kidney disease in adult patients on dialysis.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 07, 2024

blank
  • Development Update

Details:

Undisclosed


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Akebia Therapeutics

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 25, 2024

blank

07

USRC Kidney Research

Country
arrow
Pharmaconex
Not Confirmed

USRC Kidney Research

Country
arrow
Pharmaconex
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 25, 2024

blank

Details:

The agreement aims to enable access to Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for patients on dialysis.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: US Renal Care

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 10, 2024

blank

08

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : The agreement aims to enable access to Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for patients on dialysis.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

July 10, 2024

blank

Details:

Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: US Renal Care

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 09, 2024

blank

09

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 09, 2024

blank

Details:

Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for anemia due to chronic kidney disease in adult patients on dialysis.


Lead Product(s): Vadadustat,Inapplicable

Therapeutic Area: Nephrology Brand Name: Vafseo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: CSL Vifor

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2024

blank

10

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for anemia due to chronic kidney disease in adult patients on dialysis.

Product Name : Vafseo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 27, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

AKEBIA

U.S.A
CPHI Shenzhen
Not Confirmed
arrow

AKEBIA

U.S.A
arrow
CPHI Shenzhen
Not Confirmed

VADADUSTAT

Brand Name : VAFSEO

Dosage Form : TABLET;ORAL

Dosage Strength : 150MG

Approval Date : 2024-03-27

Application Number : 215192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

AKEBIA

U.S.A
CPHI Shenzhen
Not Confirmed
arrow

AKEBIA

U.S.A
arrow
CPHI Shenzhen
Not Confirmed

VADADUSTAT

Brand Name : VAFSEO

Dosage Form : TABLET;ORAL

Dosage Strength : 300MG

Approval Date : 2024-03-27

Application Number : 215192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

AKEBIA

U.S.A
CPHI Shenzhen
Not Confirmed
arrow

AKEBIA

U.S.A
arrow
CPHI Shenzhen
Not Confirmed

VADADUSTAT

Brand Name : VAFSEO

Dosage Form : TABLET;ORAL

Dosage Strength : 450MG

Approval Date : 2024-03-27

Application Number : 215192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1000025-07-9 / Vadadustat API manufacturers, exporters & distributors?

Vadadustat manufacturers, exporters & distributors 1

74

PharmaCompass offers a list of Vadadustat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vadadustat manufacturer or Vadadustat supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vadadustat manufacturer or Vadadustat supplier.

PharmaCompass also assists you with knowing the Vadadustat API Price utilized in the formulation of products. Vadadustat API Price is not always fixed or binding as the Vadadustat Price is obtained through a variety of data sources. The Vadadustat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Vadadustat

Synonyms

1000025-07-9, Akb-6548, Pg-1016548, Vadadustat [usan], N-(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, B506

Cas Number

1000025-07-9

Unique Ingredient Identifier (UNII)

I60W9520VV

About Vadadustat

Vadadustat is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, vadadustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.

Vadadustat Manufacturers

A Vadadustat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vadadustat, including repackagers and relabelers. The FDA regulates Vadadustat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vadadustat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Vadadustat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Vadadustat Suppliers

A Vadadustat supplier is an individual or a company that provides Vadadustat active pharmaceutical ingredient (API) or Vadadustat finished formulations upon request. The Vadadustat suppliers may include Vadadustat API manufacturers, exporters, distributors and traders.

click here to find a list of Vadadustat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Vadadustat KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Vadadustat Drug Master File in Korea (Vadadustat KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vadadustat. The MFDS reviews the Vadadustat KDMF as part of the drug registration process and uses the information provided in the Vadadustat KDMF to evaluate the safety and efficacy of the drug.

After submitting a Vadadustat KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vadadustat API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Vadadustat suppliers with KDMF on PharmaCompass.

Vadadustat GMP

Vadadustat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vadadustat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vadadustat GMP manufacturer or Vadadustat GMP API supplier for your needs.

Vadadustat CoA

A Vadadustat CoA (Certificate of Analysis) is a formal document that attests to Vadadustat's compliance with Vadadustat specifications and serves as a tool for batch-level quality control.

Vadadustat CoA mostly includes findings from lab analyses of a specific batch. For each Vadadustat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vadadustat may be tested according to a variety of international standards, such as European Pharmacopoeia (Vadadustat EP), Vadadustat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vadadustat USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty